I-MAB-SPONSORED ADR (IMAB) Fundamental Analysis & Valuation

NASDAQ:IMAB • US44975P1030

4.63 USD
-0.01 (-0.22%)
At close: Oct 29, 2025
4.72 USD
+0.09 (+1.94%)
After Hours: 10/29/2025, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This IMAB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to IMAB. IMAB was compared to 519 industry peers in the Biotechnology industry. While IMAB has a great health rating, there are worries on its profitability. IMAB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. IMAB Profitability Analysis

1.1 Basic Checks

  • IMAB had negative earnings in the past year.
  • IMAB had negative earnings in 4 of the past 5 years.
  • IMAB had negative operating cash flow in 4 of the past 5 years.
IMAB Yearly Net Income VS EBIT VS OCF VS FCFIMAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -500M -1B -1.5B -2B -2.5B

1.2 Ratios

  • The Return On Assets of IMAB (-18.22%) is better than 77.61% of its industry peers.
  • IMAB's Return On Equity of -19.14% is amongst the best of the industry. IMAB outperforms 84.70% of its industry peers.
Industry RankSector Rank
ROA -18.22%
ROE -19.14%
ROIC N/A
ROA(3y)-42.75%
ROA(5y)-32.49%
ROE(3y)-60.9%
ROE(5y)-45.09%
ROIC(3y)N/A
ROIC(5y)N/A
IMAB Yearly ROA, ROE, ROICIMAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for IMAB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMAB Yearly Profit, Operating, Gross MarginsIMAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. IMAB Health Analysis

2.1 Basic Checks

  • IMAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for IMAB has been increased compared to 1 year ago.
  • IMAB has more shares outstanding than it did 5 years ago.
  • IMAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IMAB Yearly Shares OutstandingIMAB Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
IMAB Yearly Total Debt VS Total AssetsIMAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • IMAB has an Altman-Z score of 23.66. This indicates that IMAB is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 23.66, IMAB belongs to the top of the industry, outperforming 91.60% of the companies in the same industry.
  • There is no outstanding debt for IMAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 23.66
ROIC/WACCN/A
WACC8.67%
IMAB Yearly LT Debt VS Equity VS FCFIMAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B

2.3 Liquidity

  • IMAB has a Current Ratio of 22.86. This indicates that IMAB is financially healthy and has no problem in meeting its short term obligations.
  • IMAB's Current ratio of 22.86 is amongst the best of the industry. IMAB outperforms 95.90% of its industry peers.
  • IMAB has a Quick Ratio of 22.86. This indicates that IMAB is financially healthy and has no problem in meeting its short term obligations.
  • IMAB has a Quick ratio of 22.86. This is amongst the best in the industry. IMAB outperforms 95.90% of its industry peers.
Industry RankSector Rank
Current Ratio 22.86
Quick Ratio 22.86
IMAB Yearly Current Assets VS Current LiabilitesIMAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. IMAB Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 89.81% over the past year.
  • Looking at the last year, IMAB shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)89.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.65%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • IMAB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.68% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y89.8%
EPS Next 2Y29.17%
EPS Next 3Y14.99%
EPS Next 5Y9.68%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMAB Yearly Revenue VS EstimatesIMAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2028 2029 2030 2031 2032 0 500M 1B 1.5B
IMAB Yearly EPS VS EstimatesIMAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.5 -0.5 -1 -1.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. IMAB Valuation Analysis

4.1 Price/Earnings Ratio

  • IMAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year IMAB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMAB Price Earnings VS Forward Price EarningsIMAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMAB Per share dataIMAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as IMAB's earnings are expected to grow with 14.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.17%
EPS Next 3Y14.99%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IMAB Dividend Analysis

5.1 Amount

  • No dividends for IMAB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

IMAB Fundamentals: All Metrics, Ratios and Statistics

I-MAB-SPONSORED ADR

NASDAQ:IMAB (10/29/2025, 8:00:02 PM)

After market: 4.72 +0.09 (+1.94%)

4.63

-0.01 (-0.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-20
Earnings (Next)04-01
Inst OwnersN/A
Inst Owner Change10.79%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap533.68M
Revenue(TTM)N/A
Net Income(TTM)-37.71M
Analysts85
Price Target8.5 (83.59%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.51%
Min EPS beat(2)-61.76%
Max EPS beat(2)54.75%
EPS beat(4)1
Avg EPS beat(4)-12.75%
Min EPS beat(4)-61.76%
Max EPS beat(4)54.75%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)19.05%
PT rev (3m)38.89%
EPS NQ rev (1m)-12.5%
EPS NQ rev (3m)-12.5%
EPS NY rev (1m)39.39%
EPS NY rev (3m)61.54%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.71
P/tB 2.71
EV/EBITDA N/A
EPS(TTM)-0.43
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS1.71
TBVpS1.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -18.22%
ROE -19.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.75%
ROA(5y)-32.49%
ROE(3y)-60.9%
ROE(5y)-45.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.86
Quick Ratio 22.86
Altman-Z 23.66
F-ScoreN/A
WACC8.67%
ROIC/WACCN/A
Cap/Depr(3y)76.01%
Cap/Depr(5y)97.76%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)89.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.65%
EPS Next Y89.8%
EPS Next 2Y29.17%
EPS Next 3Y14.99%
EPS Next 5Y9.68%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-161.06%
EBIT Next 3Y34.96%
EBIT Next 5Y74.68%
FCF growth 1Y56.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y56.04%
OCF growth 3YN/A
OCF growth 5YN/A

I-MAB-SPONSORED ADR / IMAB FAQ

What is the fundamental rating for IMAB stock?

ChartMill assigns a fundamental rating of 3 / 10 to IMAB.


What is the valuation status of I-MAB-SPONSORED ADR (IMAB) stock?

ChartMill assigns a valuation rating of 0 / 10 to I-MAB-SPONSORED ADR (IMAB). This can be considered as Overvalued.


Can you provide the profitability details for I-MAB-SPONSORED ADR?

I-MAB-SPONSORED ADR (IMAB) has a profitability rating of 1 / 10.


Can you provide the financial health for IMAB stock?

The financial health rating of I-MAB-SPONSORED ADR (IMAB) is 8 / 10.